Logo

Myriad Genetics Folate Receptor Alpha Biomarker

Jun 01, 2023

Myriad Genetics said that it has added folate receptor alpha (FRα) to its Precise Oncology Solutions portfolio. The new biomarker adds a companion diagnostic option for healthcare providers to help guide treatment decisions for patients with ovarian cancer. FRα establishes patient eligibility for Immunogen's Elahere(mirvetuximab soravtansine-gynx), the only US Food and Drug Administration-approved drug for patients who are FRα-positive and resistant to platinum-based chemotherapy. FRα is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer, Myriad noted. The new biomarker can be ordered from Myriad alongside other companion diagnostic tests, and oncologists can also choose to receive germline, HRD, FRα biomarker, and tumor testing results from a single laboratory.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.